ProStent Coronary Drug-Eluting Stent

Inclusion Criteria: 1. Age 18-75 years, men or unpregnant women; 2. Angina pectoris patients with non-symptom myocardial ischemia, or patients with obsolete myocardial infarction; 3. Total of lesion artery ≤2; 4. Lesion artery ≤30 mm in length, 2.5 to 4.0 mm in diameter (ocular estimate); 5. Narrow level of lesion artery ≥70% in diameter (ocular estimate); 6. Amount of same stents implanted in a lesion artery ≤2; 7. Patients with indications of coronary artery bridging surgery(coronary artery bypass transplant technique); 8. Patients knowing about the objective of trial, willing to sign a statement of informed consent and join in this trial, and willing to accept fellow-up Exclusion Criteria: 1. Patients with acute myocardial infarction in recent one month; 2. Chronic total occlusion lesions(TIMI 0 grade blood flow prior to implantation), left trunk vessel lesion, three-branch lesions needing treated, fork and bridge vessel lesions of branch vessels whose diameter ≥2.5mm; 3. Severe calcific lesions and twisted lesions which cannot be pre-expanded, and lesions unsuitable for delivering and expanding stents; 4. In-stent restenosis lesions; 5. Patients with stent implantation in his/her coronary artery within recent one year; 6. Severs heart failure(over NYHA III grade ), or left ventricular ejection fraction(LVEF)\< 40%( supersonic inspection or left ventricular radiography ); 7. Kidney functional damage prior to implantation, serum creatinine level\>2.0mg/dl; 8. Patients with hemorrhage tendency, an active digestive ulcer history, a cerebral hemorrhage or subarachnoid hemorrhage history, or cerebral apoplexy within half a year, and these patients who contraindicate against platelet inhibitors and anticoagulant therefore can not bear anticoagulation treatment; 9. Patients allergic to aspirin, clopidogrel or ticlopidine, heparin, contrast medium, rapamycin and metals; 10. Patients whose life expectancy less than 12 months; 11. Patients who are participating in other drugs or medical devices clinical trials; 12. Patients who can not comply with the clinical trial protocol; 13. Patients having a heart transplant.